For a small biotech, $NGM just added the 10th director to its board. Maybe investors are afraid of its shelf filing but $MRK could easily swallow it since the two are involved in the whole pipeline except its NASH candidate in PII. Insider buying is quite substantive https://t.co/yFTTxypED2